Cao Minyue, Yan Jiayu, Ding Yan, Zhang Yiqin, Sun Yihan, Jiang Genyi, Zhang Yanli, Li Bilan
Shanghai Key Laboratory of Maternal Fetal Medicine, Shanghai Institute of Maternal-Fetal Medicine and Gynecologic Oncology, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University, Shanghai, 200092, China.
Cell Death Dis. 2025 Mar 3;16(1):148. doi: 10.1038/s41419-025-07458-7.
RNA splicing controls the post-transcriptional level of gene expression, allowing for the synthesis of many transcripts with various configurations and roles. Variations in RNA splicing regulatory factors, including splicing factors, signaling pathways, epigenetic modifications, and environmental factors, are typically the origin of tumor-associated splicing anomalies. Furthermore, thorough literature assessments on the intricate connection between tumor-related splicing dysregulation and tumor immunity are currently lacking. Therefore, we also thoroughly discuss putative targets associated with RNA splicing in endometrial cancer (EC) and the possible impacts of aberrant RNA splicing on the immune control of tumor cells and tumor microenvironment (TME), which contributes to enhancing the utilization of immunotherapy in the management of EC and offers an alternative viewpoint for the exploration of cancer therapies and plausible prognostic indicators.
RNA剪接控制基因表达的转录后水平,使得能够合成具有各种结构和功能的多种转录本。RNA剪接调控因子的变异,包括剪接因子、信号通路、表观遗传修饰和环境因素,通常是肿瘤相关剪接异常的根源。此外,目前缺乏对肿瘤相关剪接失调与肿瘤免疫之间复杂联系的全面文献评估。因此,我们还深入讨论了子宫内膜癌(EC)中与RNA剪接相关的假定靶点,以及异常RNA剪接对肿瘤细胞免疫控制和肿瘤微环境(TME)的可能影响,这有助于提高免疫疗法在EC治疗中的应用,并为探索癌症治疗方法和合理的预后指标提供了另一种观点。